Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
RCUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.50 - $18.98
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.14M
Market Cap
$878.85M
Enterprise Value$546.41M
Total Cash (Recent Filing)-$98.90M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.97
Next Earnings
May 06, 2025EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding105,885,140
10 Day Avg. Volume1,335,735
30 Day Avg. Volume1,142,132
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.12
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$29.13Price Target Upside250.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Arcus Biosciences News
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyData presented bolstered the promising topline results presented in October 2024, and validated cas as a best-in-class HIF-2α compared to competitor belzutifan.
Financial PositionRCUS finished 2024 in a strong cash position, with $992M in cash and cash equivalents expected to fund operations into mid-2027.
Market OpportunityRCUS retains full rights to casdatifan, with a potential market opportunity of approximately $5 billion in the post-immuno-oncology and immuno-oncology-naive metastatic ccRCC combinations.
Bears Say
Investor ConcernsInvestors have expressed hesitation stemming from Gilead’s decision not to opt-in to the program and whether cas’s differentiation over Merck’s belzutifan will prove clinically meaningful.
Strategic DecisionsContrary to expectations given the promising data, GILD chose not to opt-in for commercial rights to cas, driven by strategic concerns.
---
Ownership Overview
6.46% Insiders
15.23% Mutual Funds
51.34% Other Institutional Investors
11.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $18.98 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Arcus Biosciences Inc’s market cap is $878.85M.
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is May 06, 2025 which is in 9 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Feb 25, 2025. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.249 by $0.219.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -1.03.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 105,885,140 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.249. Following the earnings report the stock price went down -0.977%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Currently, no hedge funds are holding shares in RCUS
---
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.13 (250.96% Upside)
$29.13 (250.96% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 11.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.65%
12-Months-Change
Fundamentals
Return on Equity
-59.77%
Trailing 12-Months
Asset Growth
5.02%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences (RCUS) is a biopharmaceutical company that focuses on developing innovative cancer immunotherapies. The company is engaged in the research and development of novel combination therapies designed to enhance the immune system's ability to fight cancer. Arcus Biosciences' pipeline includes small molecules and antibodies, targeting various pathways to improve patient outcomes in oncology.
---
RCUS Stock 12 Month Forecast
Average Price Target
$29.13
▲(250.96% Upside)
Technical Analysis
Intellia Therapeutics
―
Xeris Pharmaceuticals
―
Vir Biotechnology
―
Nurix Therapeutics
―
Day One Biopharmaceuticals
―
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
6/21 ratings generated profit
1 Year Average Return
-19.20%
reiterated a buy rating 6 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -19.20% per trade.
---